• Pexidartinib (PLX3397): Technical Guidance for CSF1R Inhibit

  2026-04-23

  Pexidartinib (PLX3397) is a selective ATP-competitive CSF1R inhibitor designed for research applications involving macrophage modulation and tumor microenvironment studies. It is best suited for workflows investigating CSF1R-mediated signaling inhibition and apoptosis induction in cancer models. Its use is not recommended in diagnostic or clinical settings, nor for long-term solution storage.

• Lysoptosis: Conserved Cell Death Pathway Defined by Serpin M

  2026-04-22

  Luke et al. (2022) identify lysoptosis as a distinct, evolutionarily conserved lysosome-dependent cell death (LDCD) pathway, characterized by lysosomal membrane permeabilization and cathepsin release, and regulated by intracellular serpins. This work clarifies the mechanistic role of cysteine proteases in cell death and has implications for experimental modulation of apoptosis and related pathways.

• CX-5461: Applied Workflows for RNA Polymerase I Inhibition i

  2026-04-22

  CX-5461, a potent RNA polymerase I inhibitor, enables precise interrogation of ribosome biogenesis and solid tumor growth inhibition in translational cancer models. This guide distills recent high-impact findings and offers pragmatic protocols and troubleshooting strategies for maximizing experimental reliability and translational relevance.

• TCF25 Drives Lysosomal Acidification and Cell Death via V-AT

  2026-04-21

  Ren et al. identify TCF25 as a critical nutrient sensor that enhances lysosomal acidification through V-ATPase activity during glucose starvation, orchestrating both metabolic adaptation and lysosome-dependent cell death. These findings offer mechanistic insight into nutrient stress responses and suggest new intervention points for metabolic and ischemic disorders.

• ABT-888 (Veliparib): Advanced PARP Inhibition in MSI Tumor M

  2026-04-21

  Explore the unique mechanisms of ABT-888 (Veliparib) as a potent PARP inhibitor, with an in-depth analysis of its role in DNA repair inhibition and combination therapies for microsatellite instability (MSI) tumor models. Discover differentiated insights, protocol guidance, and the latest scientific findings.

• HyperScript™ Reverse Transcriptase: Unraveling RNA Complexit

  2026-04-20

  Explore how HyperScript™ Reverse Transcriptase empowers precise cDNA synthesis for qPCR, especially in the context of endoplasmic reticulum (ER) stress and complex RNA templates. This article uniquely bridges advanced enzyme technology with cutting-edge stem cell research.

• Coumestrol Induces Ferroptosis in RA Synoviocytes via PMAIP1

  2026-04-20

  This study demonstrates that Coumestrol, a phytoestrogen estrogen receptor antagonist, induces ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes by stabilizing mitochondrial PMAIP1 through TRIM3 inhibition. The findings reveal a novel mechanism for suppressing synovial proliferation and inflammation, highlighting Coumestrol’s promise as a candidate for targeted RA therapies.

• Peptidisc-Enabled Nanobody Multimerization for Polybody Engi

  2026-04-19

  Chen and Duong van Hoa present a peptidisc-assisted strategy for hydrophobic clustering, enabling the assembly of multimeric and multispecific nanobody proteins ('polybodies'). This approach enhances nanobody affinity and versatility, expanding the protein engineering toolkit for advanced biochemical applications.

• Ferritin-Based Hybrid Protein Particles for Combination Vacc

  2026-04-18

  This study introduces a ferritin-based hybrid protein particle vaccine integrating influenza A M2e and SARS-CoV-2 S-protein epitopes into a single nanostructure. The approach enables simultaneous multivalent antigen display and enhances immunogenicity, offering a scalable route to combination vaccine development with robust functional responses.

• Thrombin as a Trypsin-like Serine Protease: Applied Protocol

  2026-04-17

  Unlock the full experimental power of thrombin in coagulation, vascular modeling, and platelet research. This guide details advanced workflows, troubleshooting strategies, and comparative protocol enhancements using APExBIO’s high-purity Coagulation Factor II (Thrombin) B Chain Fragment.

• Bazedoxifene Inhibits IL-6/GP130 Signaling: Implications for

  2026-04-16

  This review highlights bazedoxifene's novel role as an IL-6/GP130 pathway inhibitor in multiple cancer models, expanding its clinical potential beyond osteoporosis. The paper synthesizes evidence for bazedoxifene’s direct interference in pro-tumorigenic signaling and examines its impact on tumor progression and synergy with established chemotherapeutics.

• Targeting FGFR2 Fusions in ICC via Heteroduplex Oligonucleot

  2026-04-15

  This study introduces a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide (Cho-HDO) that specifically suppresses FGFR2 fusion oncogenes in intrahepatic cholangiocarcinoma (ICC), revealing a mechanism of resistance involving asparagine metabolism. The findings lay groundwork for combinatorial therapies targeting both FGFR2 fusions and metabolic adaptation, with implications for the precision treatment of ICC.

• Bismuth Subsalicylate: Protocols for GI Disorder Research

  2026-04-14

  Bismuth Subsalicylate is a high-purity solid compound tailored for inflammation pathway modulation and gastrointestinal disorder research. It is best suited for experimental models investigating diarrhea or upset stomach symptom relief where robust inhibition of prostaglandin G/H synthase 1/2 is required. This reagent should not be used in diagnostic or clinical workflows, and special care must be taken with solubility and storage.

• Dissecting In Vitro Drug Response Metrics in Cancer Research

  2026-04-13

  Schwartz's dissertation redefines in vitro drug response evaluation by clarifying the distinction and interplay between relative and fractional viability metrics. This work provides methodological guidance for interpreting anti-cancer compound effects on proliferation and cell death, with implications for assay design and translational cancer biology.

• Monomeric Amyloid Beta Signaling Modulates Microglia in Brai

  2026-04-13

  A recent eLife study reveals that monomeric amyloid beta activates a novel signaling pathway that inhibits microglial activation, thereby influencing mouse neocortical development. These findings challenge the traditional view of amyloid beta solely as a pathological agent in Alzheimer's disease and suggest a physiological role for monomeric forms in brain maturation.

16716 records 1/1115 page Next 12345 下5页 Last page